Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms
Gauthier K, Bai A, Perras C, Cunningham J, Ahuja T, Richter T, Kovacs C
Record ID 32012000711
English
Authors' recommendations:
Evidence from six placebo-controlled randomized controlled trials revealed that denosumab and zoledronic acid reduced the risk of vertebral, hip, and non-vertebral fractures in postmenopausal women with osteoporosis. Raloxifene was associated with a reduced incidence of vertebral fractures, but evidence was limited regarding hip and non-vertebral fractures, suggesting that it may not be effective in preventing such outcomes. Harms data did not raise new safety concerns; however, specific harms profiles should be considered when selecting treatment.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.cadth.ca/media/pdf/tr0001_Osteoporosis_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antibodies, Monoclonal
- Bone Density Conservation Agents
- Raloxifene Hydrochloride
- Diphosphonates
- Imidazoles
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.